NovaLead’s patented repurposed drug gets CDSCO nod for DFU patients in India
The drug is a novel topical gel formulation of Esmolol hydrochloride
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
NovaLead Pharma
Drug repurposing and its growing significance in India
Supreet Deshpande, CEO, NovaLead Pharma talks about how drug repurposing, with its priceless abilities to save time and millions…
Computational methodologies can be effective in predicting and prioritising key targets related to…
Supreet Deshpande, CEO, NovaLead Pharma shares more insights on how computational technologies can revolutionise pharma R&D…
Embracing the power of data
The pharma sector needs to improve its capabilities in data gathering and analysis with the help of AI and computational…
Novalead Pharma says 42 existing drugs can help in treating coronavirus patients
The conclusions of the startup, which is backed by Tata Capital Healthcare Fund, are based on a study of 2,100 approved drugs and…
NovaLead Pharma commences Phase 3 Clinical Trial of Its Novel Topical Drug Galnobax for DFU
Subject to satisfactory completion of Phase 3 trial, Galnobax can be a path-breaking treatment for Diabetic Foot Ulcer (DFU)
NovaLead Pharma completes global phase I /II clinical trial for Galnobax
Galnobax, a topical gel, will help in the treatment of diabetic foot ulcer NovaLead Pharma announced a potential breakthrough…